Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study).

"Ph1b Escalation~Drug: \[²¹²Pb\]Pb-ADVC001administered intravenously per dose escalation scheme~Dose Level 1~\- 60 MBq, 4 cycles every 6 weeks~Dose Level 2a~\- 120 MBq, 4 to 6 cycles every 4 weeks~Dose Level 2b~\- Optional cohort of 120 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3a~\- 160 MBq, 4 to 6 cycles every 4 weeks~Dose Level 3b~\- Optional cohort of 160 MBq, 4 to 6 cycles every 2 weeks~Dose Level 3c~\- Optional cohort of 160 MBq, 4 to 6 cycles every week~Dose Level 4a~* 200 MBq, 4 to 6 cycles every 4 weeks~Dose Level 4b~\- Optional cohort of 200 MBq, 4 to 6 cycles every 2 weeks~Dose Level 4c~\- Optional cohort of 200MBq, 4 to 6 cycles every week~Ph2a Expansion~Drug: \[²¹²Pb\]Pb-ADVC001 at recommended phase 2 dose and schedule"